Miami, FL – Heat Biologics, a clinical-stage immunotherapy company focused on developing off-the-shelf drugs to combat a wide range of diseases, has closed on an initial funding round in an undisclosed amount led by Brightline Ventures. (more…)

Raleigh, NC - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has entered into an agreement to sell $300 million aggregate principal amount of its 2.75% convertible senior notes due 2015. (more…)

Chapel Hill, NC - POZEN Inc. (NASDAQ: POZN), announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration (FDA) approval of VIMOVOâ„¢ (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application (IND) and New Drug Application (NDA) for VIMOVO to AstraZeneca over the next few weeks. (more…)

Washington, DC – The U.S. Department of the Treasury today announced the guidelines for applying for the new Therapeutic Discovery Project Program created by the Affordable Care Act. The program will provide tax credits and grants to small firms that show significant potential to produce new and cost-saving therapies, support good jobs and increase U.S. competitiveness. (more…)

Durham, NC – Oncoscope, a medical device company that develops proprietary optical imaging systems, has raised nearly $2 million of a mixed equity, debt and securities offering targeted at just over $1.5 million, according to a regulatory filing. (more…)

Marietta, GA – Q Care International, a company that sells a portable device for disposing of used hypodermic needles, has raised $2.64 million of a $4.5 million in equity, according to a regulatory filing. (more…)

Atlanta, GA - CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company’s CHAMPION clinical trial. (more…)

Morrisville, NC - TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. (more…)